Promote a healthier life
for humankind through
advancements in science

Science-based

Benefit the patients with
high-quality medication as
we determined to innovate

Innovation-driven

Build a leading global
biopharmaceutical group
to serve more

Going Global

Fulfill social responsibilities
through accountable actions

Embrace Social
Responsibilities

Explore who we are

About us

Innovation is the core of our development strategy

Partnering

We are actively looking for synergistic partnerships

Walk into Hengrui

Est.

1970

New Molecular Entity drugs marketed in China

26

Other innovative drugs marketed in China

6

SH 600276

HK 1276

Est.

1970

Marketed Innovative Products in China

8

Partnered Innovative Product Launched

1

SH 600276

HK 1276

Pipeline

Our innovative pipeline covers the most of major therapeutic areas and continues to grow

Pipeline

Our innovative pipeline covers the most of major therapeutic areas and continues to grow

Investor

Enhance communication between our company and investors

Media

HbA1c Reduction of Up to 2.78%: Hengrui Pharma Reports Positive Topline Data from Phase 3 Trial in China of GLP-1/GIP Dual Receptor Agonist Ribupatide Injection in Adults with Type 2 Diabetes Inadequately Controlled with Oral Antidiabetic Treatment

Media

HbA1c Reduction of Up to 2.67%: Hengrui Pharma Reports Positive Topline Data from Phase 3 Trial in China of GLP-1/GIP Dual Receptor Agonist Ribupatide Injection in Treatment-Naïve T2DM Patients

Media

Hengrui Pharma Receives Complete Response Letter from FDA for Camrelizumab in Combination with Rivoceranib for Unresectable or Metastatic Hepatocellular Carcinoma